Vonoprazan fumarate

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H16FN3O2S.C4H4O4
Molecular Weight	461.463
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CC=CN=C3

InChI

InChIKey=ROGSHYHKHPCCJW-WLHGVMLRSA-N

InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI

Molecular Formula	C17H16FN3O2S
Molecular Weight	345.391
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.takeda.com/news/2015/20150226_6922.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25744862| https://www.ncbi.nlm.nih.gov/pubmed/20624992

Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 38 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992	Blocker 555		0.003 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Gastric ulcer 74 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8583	TAKECAB Approved Use Unknown
Duodenal ulcer 49 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8583	TAKECAB Approved Use Unknown
Reflux esophagitis 3 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8583	TAKECAB Approved Use Unknown
Helicobacter pylori gastritis 3 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Primary	Approved 8583	TAKECAB Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
71.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
129.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
303.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
38.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
51.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
38.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
48.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
62 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
75.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
37.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
58.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
59.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
4.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
31.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
60.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
161.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
474.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
911.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1985 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
59.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
109.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
169.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
289.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
475.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
61.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
79.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
97.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
112.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
121.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
151.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
231.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
291.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
391.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
458.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
104.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
177.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
195.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
255.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
338.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
420.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
488.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26111126/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25707624/	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26369775/			VONOPRAZAN plasma	Homo sapiens population: HEALTHY age: sex: food status:
12% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400256_3399103F1020_1_006_1F.pdf#page=46 \| https://pubmed.ncbi.nlm.nih.gov/26369775/			VONOPRAZAN plasma	Homo sapiens

Doses

Dose	Population	Adverse events
40 mg 1 times / day multiple, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25707624/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/25707624/	Sources: https://pubmed.ncbi.nlm.nih.gov/25707624/
40 mg single, oral Highest studied dose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27928738/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27928738/	Sources: https://pubmed.ncbi.nlm.nih.gov/27928738/
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	Disc. AE: Diarrhoea, ALT increased... AEs leading to discontinuation/dose reduction: Diarrhoea (0.4%) ALT increased (0.4%) AST increased (0.4%) Bile duct stone (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/

AEs

AE	Significance	Dose	Population
ALT increased	0.4% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/
AST increased	0.4% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/
Bile duct stone	0.4% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/
Diarrhoea	0.4% Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/31409606/

PubMed

Title	Date	PubMed
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.	2010-10	20624992

Patents

Sample Use Guides

In Vivo Use Guide

Orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.

Route of Administration: Oral

In Vitro Use Guide

TAK-438 (Vonoprazan) inhibited H(+),K(+)-ATPase activity in porcine gastric microsomes with IC(50) values of 0.019 μM at pH 6.5. The inhibitory activity of TAK-438 was unaffected by ambient pH. The inhibition by TAK-438 was reversible and achieved in a K(+)-competitive manner.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:04:05 GMT 2025` Edited by `admin` on `Mon Mar 31 21:04:05 GMT 2025`
Record UNII	4QW3X4AMLB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Vonoprazan fumarate

Common Name

English

TAKECAB

Preferred Name

English

TAK-438

Code

English

VOCINTI

Brand Name

English

Vonoprazan monofumarate

Common Name

English

Vonoprazan fumarateE [JAN]

Common Name

English

VOQUEZNA

Brand Name

English

1H-Pyrrole-3-methanamine, 5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, (2E)-2-butenedioate (1:1)

Systematic Name

English

5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate (1:1)

Systematic Name

English

TAK438

Code

English

Vonoprazan fumarate [MI]

Common Name

English

TAK-438 monofumarate

Common Name

English

Vonoprazan fumarate [WHO-DD]

Common Name

English

Code System Code Type Description

RXCUI

2604576